HER3 Breast Text Module

CME

Elevating the Science of HER3-Targeted Therapy to Improve Outcomes in Breast Cancer

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: October 13, 2023

Expiration: October 12, 2024

Yuan Yuan
Yuan Yuan, MD, PhD

Activity

Progress
1
Course Completed

Introduction

In this module, Yuan Yuan, MD, PhD, describes the current understanding of HER3 as an emerging therapeutic target for the treatment of breast cancer. This includes background on the role of HER3 in oncogenic signaling pathways in conjunction with other members of the human epidermal growth factor receptor family, up-to-date available clinical trial data and ongoing trials investigating HER3-targeting agents in breast cancer, and potential sequencing considerations for a HER3-targeted antibody–drug conjugate (ADC) in a treatment landscape already including several targeted ADCs.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with breast cancer do you provide care for in a typical month?

In an ongoing phase II trial of patritumab deruxtecan that enrolled patients with previously treated HER2-negative advanced breast cancer, what was the lowest level of HER3 expression associated with antitumor activity?